Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines.
Ontology highlight
ABSTRACT: Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec, which provides long-lasting basal insulin coverage, and insulin aspart, which targets postprandial glycaemia. This review provides expert opinion on the practical clinical use of IDegAsp, including: dose timings relative to meals, when and how to intensify treatment from once-daily (OD) to twice-daily (BID) dose adjustments, and use in special populations (including hospitalized patients). IDegAsp could be considered as one among the choices for initiating insulin treatment, preferential to starting on basal insulin alone, particularly for people with severe hyperglycaemia and/or when postprandial hyperglycaemia is a major concern. The recommended starting dose of IDegAsp is 10 units with the mos
SUBMITTER: Mehta R
PROVIDER: S-EPMC7689716 | biostudies-literature | 2020 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA